Abstract
Autoreactive cytotoxic T cells play a key role in the pathogenesis of aplastic anemia (AA) by myelosuppressive cytokines including interferon-gamma, tumor necrosis factor alpha, and transforming growth factor beta. The purpose of this study is to determine which single nucleotide polymorphisms (SNPs) in cytokine genes were relevant to AA risk and whether the relevant SNPs were associated with response to immunosuppressive therapy (IST). Among 84 screened patients, 80 patients confirmed as having acquired AA, and 84 age- and sex-matched healthy controls were analyzed consecutively. We genotyped ten polymorphisms in three cytokine genes (IFNG, TNF, and TGFB1) and FAS gene. We assessed the association between polymorphisms and AA risk, and the association between polymorphisms and response to IST in three genetic models (dominant, recessive, and additive). The IFNG −2,353 T allele (dominant model, OR = 0.43, p = .012) and TCA haplotype (dominant model, OR = 0.50, p = .038) were significantly associated with the development of AA. In addition, this relevant IFNG −2,353 T allele and TCA haplotype were related to the response of IST (dominant model, OR = 0.076, p = .034). Concerning TGFB1, although its polymorphisms are not related to AA susceptibility, P10L T allele (recessive model, OR = 0.18, p = .038) and CT haplotype (dominant model, OR = 5.68, p = .038) were associated with response to IST. This exploratory study concurred with prior studies indicating that polymorphisms in IFNG are related to AA susceptibility. In addition, it was found that polymorphisms in IFNG and TGFB1 are associated with response to IST.
Similar content being viewed by others
References
Young N, Calado R, Scheinberg P (2006) Current concepts in the pathophysiology and treatment of aplastic anemia. Blood 108:2509
Bacigalupo A, Bruno B, Saracco P, Di Bona E, Locasciulli A, Locatelli F, Gabbas A, Dufour C, Arcese W, Testi G, Broccia G, Carotenuto M, Coser P, Barbui T, Leoni P, Ferster A (2000) Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midolio Osseo (GITMO). Blood 95:1931–1934
Fuhrer M, Rampf U, Baumann I, Faldum A, Niemeyer C, Janka-Schaub G, Friedrich W, Ebell W, Borkhardt A, Bender-Goetze C (2005) Immunosuppressive therapy for aplastic anemia in children: a more severe disease predicts better survival. Blood 106:2102–2104
Locasciulli A, Oneto R, Bacigalupo A, Socie G, Korthof E, Bekassy A, Schrezenmeier H, Passweg J, Fuhrer M (2007) Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood to Marrow Transplantation (EBMT). Haematologica 92:11–18
Dufour C, Corcione A, Svahn J, Haupt R, Battilana N, Pistoia V (2001) Interferon gamma and tumour necrosis factor alpha are overexpressed in bone marrow T lymphocytes from paediatric patients with aplastic anaemia. Br J Haematol 115:1023–1031
Sloand E, Kim S, Maciejewski JP, Tisdale J, Follmann D, Young NS (2002) Intracellular interferon-gamma in circulating and marrow T cells detected by flow cytometry and the response to immunosuppressive therapy in patients with aplastic anemia. Blood 100:1185–1191
Maciejewski J, Selleri C, Anderson S, Young NS (1995) Fas antigen expression on CD34+ human marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood 85:3183–3190
Killick SB, Cox CV, Marsh JC, Gordon-Smith EC, Gibson FM (2000) Mechanisms of bone marrow progenitor cell apoptosis in aplastic anaemia and the effect of anti-thymocyte globulin: examination of the role of the Fas-Fas-L interaction. Br J Haematol 111:1164–1169
Li MO, Flavell RA (2008) TGF-beta: a master of all T cell trades. Cell 134:392–404
Rizzo S, Killick SB, Patel S, Ball SE, Wadhwa M, Dilger P, Gordon-Smith EC, Gibson FM (1999) Reduced TGF-beta1 in patients with aplastic anaemia in vivo and in vitro. Br J Haematol 107:797–803
Dufour C, Capasso M, Svahn J, Marrone A, Haupt R, Bacigalupo A, Giordani L, Longoni D, Pillon M, Pistorio A, Di Michele P, Iori AP, Pongiglione C, Lanciotti M, Iolascon A (2004) Homozygosis for (12) CA repeats in the first intron of the human IFN-gamma gene is significantly associated with the risk of aplastic anaemia in Caucasian population. Br J Haematol 126:682–685
Gidvani V, Ramkissoon S, Sloand EM, Young NS (2007) Cytokine gene polymorphisms in acquired bone marrow failure. Am J Hematol 82:721–724
Peng J, Liu C, Zhu K, Zhu Y, Yu Y, Li J, Hou M, Chen X, Xu C, Zhang M (2003) The TNF2 allele is a risk factor to severe aplastic anemia independent of HLA-DR. Hum Immunol 64:896–901
Demeter J, Messer G, Schrezenmeier H (2002) Clinical relevance of the TNF-alpha promoter/enhancer polymorphism in patients with aplastic anemia. Ann Hematol 81:566–569
Takaku T, Calado RT, Kajigaya S, Young NS (2009) Interleukin-23 receptor (IL-23R) gene polymorphisms in acquired aplastic anemia. Ann Hematol 88:653–657
Anonymous (1987) Incidence of aplastic anemia: the relevance of diagnostic criteria. By the international agranulocytosis and aplastic anemia study. Blood 70:1718–1721
Camitta B, Thomas E, Nathan D, Santos G, Gordon-Smith E, Gale R, Rappeport J, Storb R (1976) Severe aplastic anemia: a prospective study of the effect of early marrow transplantation on acute mortality. Blood 48:63
Bacigalupo A, Hows J, Gluckman E, Nissen C, Marsh J, Van Lint M, Congiu M, De Planque M, Ernst P, McCann S (1988) Bone marrow transplantation (BMT) versus immunosuppression for the treatment of severe aplastic anaemia (SAA): a report of the EBMT* SAA Working Party. Br J Haematol 70:177–182
Camitta BM (2000) What is the definition of cure for aplastic anemia? Acta Haematol 103:16–18
Scheinberg P, Wu CO, Nunez O, Young NS (2009) Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia. Br J Haematol 144:206–216
Nistico A, Young NS (1994) Gamma-Interferon gene expression in the bone marrow of patients with aplastic anemia. Ann Intern Med 120:463–469
Pravica V, Asderakis A, Perrey C, Hajeer A, Sinnott PJ, Hutchinson IV (1999) In vitro production of IFN-gamma correlates with CA repeat polymorphism in the human IFN-gamma gene. Eur J Immunogenet 26:1–3
Pravica V, Perrey C, Stevens A, Lee JH, Hutchinson IV (2000) A single nucleotide polymorphism in the first intron of the human IFN-gamma gene: absolute correlation with a polymorphic CA microsatellite marker of high IFN-gamma production. Hum Immunol 61:863–866
Fermo E, Bianchi P, Barcellini W, Pedotti P, Boschetti C, Alfinito F, Cortelezzi A, Zanella A (2004) Immunoregulatory cytokine polymorphisms in Italian patients affected by paroxysmal nocturnal haemoglobinuria and aplastic anaemia. Eur J Immunogenet 31:267–269
Acknowledgment
This study was supported by grant title “The impact of genetic polymorphism on the prevalance and treatment outcomes of aplastic anemia” from the Korea Cancer Research Foundation and by a grant of the Korea Health 21 R&D Project, Ministry of Health & Welfare, Republic of Korea (0405-BC02-0604-0004).
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Table 1
Primer sets and Tm for the SNaPshot assay. (DOC 76 kb)
Rights and permissions
About this article
Cite this article
Lee, YG., Kim, I., Kim, J.H. et al. Impact of cytokine gene polymorphisms on risk and treatment outcomes of aplastic anemia. Ann Hematol 90, 515–521 (2011). https://doi.org/10.1007/s00277-010-1102-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-010-1102-2